Vytrus Biotech is launching Toleroxyl™ – Re-educating urban skin at in-cosmetics Korea 2026, introducing a new biotech active designed to open a new cosmetic category: the Tolerogen.
Sensitive skin is one of today’s fastest-growing consumer concerns, driven by modern lifestyles, indoor environments and continuous low-grade exposure to pollutants. Redness, tightness, burning, stinging and discomfort are common signs of skin that “overreacts” to everyday stressors. For Vytrus, this reflects a deeper biological challenge: the skin may have lost part of its ability to distinguish harmless urban stimuli from real threats.
Toleroxyl™ proposes a new cosmetic logic: train the skin, do not just silence it. Developed through Vytrus’ biotechnology platforms, the active is inspired by the skin’s own biological signals and targets Langerhans cells, the immune decision-makers of the epidermis. These cells play a central role in determining whether skin responds through inflammation or tolerance.
Its mechanism is based on GM-CSF, a human protein involved in the functional programming of Langerhans cells. By binding to GM-CSF receptors, Toleroxyl™ helps keep these skin cells in a calm, tolerance-supporting state. This promotes the release of TGF-β and helps reduce inflammatory signals such as TNF-α, IL-8 and IL-6, supporting a healthier skin environment.
In vitro studies have shown activity on key tolerogenic pathways, including RELB and SOX4, while helping normalise immunogenic markers such as CCR7, CD80 and CD86. Clinical studies in volunteers with hyperreactive skin demonstrated visible benefits, including redness reduction, erythema improvement and relief from discomfort-related signs, as well as improvement of pro-inflammatory cytokines in vivo.
For formulators, Toleroxyl™ opens new opportunities in tolerance-training skin care, anti-redness concepts, anti-pollution daily care and recovery products for overstimulated urban skin.
Discover Toleroxyl™ at in-cosmetics Korea 2026 or contact Vytrus Biotech at customer@vytrus.com for further information.
